Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CHAT | P28329 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271363 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL541687 | 0.95 | HDAC8 (0.95) | HDAC8ACHEALDH1A1CHATRAB9A | |
| Water SCHEMBL9141383 | 0.95 | HDAC8 (0.95) | HDAC8ACHEALDH1A1CHATRAB9A | |
| Iodide SCHEMBL994764 | 0.95 | HDAC8 (0.95) | HDAC8ACHEALDH1A1CHATRAB9A | |
| Iodide SCHEMBL11496800 | 0.92 | HDAC8 (0.90) | HDAC8ACHEALDH1A1CHATRAB9A | |
| Styrene SCHEMBL2988659 | 0.88 | HDAC8 (0.82) | HDAC8ACHEALDH1A1CHATRAB9A | |
| Sulfuric Acid SCHEMBL8013239 | 0.84 | HDAC8 (0.75) | HDAC8ACHEALDH1A1CHATRAB9A | |
| Sulfuric Acid SCHEMBL8013242 | 0.84 | HDAC8 (0.75) | HDAC8ACHEALDH1A1CHATRAB9A | |
| Bicarbonate SCHEMBL31648035 | 0.84 | HDAC8 (0.75) | HDAC8ACHEALDH1A1CHATRAB9A | |
| Sulfuric Acid SCHEMBL8013244 | 0.83 | HDAC8 (0.72) | HDAC8ACHEALDH1A1CHATRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061062-A1 | MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM | UNIV NEBRASKA (US) | 2026-03-05 | — | — | US | claimed |
| WO-2025132734-A1 | ANIONIC CONDUCTOR | OXECO U.K. LIMITED (GB) | 2025-06-26 | — | — | WO | claimed |
| US-11920043-B2 | Method of manufacturing non-sintered liquid metal ink | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-03-05 | — | — | US | claimed |
| US-20230159771-A1 | METHOD OF MANUFACTURING NON-SINTERED LIQUID METAL INK | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-05-25 | — | — | US | claimed |
| EP-4071218-A1 | METHOD FOR PRODUCING NON-SINTERED LIQUID METAL INK | Korea Advanced Institute Of Science And Technology (KR) | 2022-10-12 | — | — | EP | claimed |
| WO-2022154312-A1 | METHOD FOR PRODUCING NON-SINTERED LIQUID METAL INK | 한국과학기술원 | 2022-07-21 | — | — | WO | claimed |
| US-20220008543-A1 | MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-13 | — | — | US | claimed |
| CN-113226376-A | Thermosensitive injectable gels based on macromolecular prodrugs as novel drug delivery platform | 内布拉斯加大学董事会 | 2021-08-06 | — | — | CN | claimed |
| EP-3269394-A1 | MACROMOLECULAR DELIVERY SYSTEMS FOR NON-INVASIVE IMAGING, EVALUATION AND TREATMENT OF ARTHRITIS AND OTHER INFLAMMATORY DISEASES | University of Utah Research Foundation (US) | 2018-01-17 | — | — | EP | claimed |
| US-20160166693-A1 | RADIATION ENHANCED MACROMOLECULAR DELIVERY OF THERAPEUTIC AGENTS FOR CHEMOTHERAPY | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-06-16 | — | — | US | claimed |
| WO-2004062588-A2 | WATER-SOLUBLE POLYMERIC BONE-TARGETING DRUG DELIVERY SYSTEM | UNIVERSITY OF UTAH (US) | 2004-07-29 | — | — | WO | claimed |
| EP-1390020-A1 | A COATED FILM LAMINATE HAVING AN IONIC SURFACE | 3M Innovative Properties Company (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030168629-A1 | Reactive liquid polymer crosslinking agent and process for preparation | LCB WORLDWIDE, INC. | 2003-09-11 | — | — | US | claimed |
| WO-2003019134-A2 | IMMUNOASSAYS USING AN AZLACTONE-MODIFIED POLYMERIC SUBSTRATE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-03-06 | — | — | WO | claimed |
| US-20030040125-A1 | Methods for performing immunological assays | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-27 | — | — | US | claimed |
| WO-2002088839-A2 | METHOD OF TRANSFERRING MOLECULES TO A COATED FILM LAMINATE HAVING AN IONIC SURFACE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-11-07 | — | — | WO | claimed |
| WO-2002087551-A1 | A COATED FILM LAMINATE HAVING AN IONIC SURFACE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-11-07 | — | — | WO | claimed |
| US-20020160367-A1 | Coated film laminate having an ionic surface | 3M INNOVATIVE PROPERTIES COMPANY | 2002-10-31 | — | — | US | claimed |
| US-20020160530-A1 | Method of transferring molecules to a coated film laminate having an ionic surface | 3M INNOVATIVE PROPERTIES COMPANY | 2002-10-31 | — | — | US | claimed |
| US-5525450-A | QUATERNARY AMMONIUM AND ACID GROUP CONTAINING POLYMER SEGMENTS IN NONPOLAR LIQUID | XEROX CORPORATION (US) | 1996-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166693-A1 | RADIATION ENHANCED MACROMOLECULAR DELIVERY OF THERAPEUTIC AGENTS FOR CHEMOTHERAPY | MRE11, TOP2A, MTREX | ACHE 4058/4885HDAC8 1530/4885ALDH1A1 3281/4885 |
| US-20260061062-A1 | MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM | CD44, ALG1, HSF1 | ACHE 2028/4885HDAC8 919/4885ALDH1A1 993/4885 |
| US-20220008543-A1 | MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM | PLG, PYGL, PPIG | ACHE 3459/4885HDAC8 714/4885ALDH1A1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.